About HIS Eyeness
HIS Eyeness is a Healthcare company based in Bengaluru (India) founded in 2017. Eye drops for treating infections and inflammations are developed. HIS Eyeness has raised $980.13 thousand across 5 funding rounds from investors including Bisi Reddy, Nandini S Nelivigi and Krimali Manthan Thacker. The company has 90 employees. HIS Eyeness was last valued at $1.35 million in April 2022. Its Indian entity His Eyeness Ophthalmics Private Limited reported revenue of ₹52.92 Cr. HIS Eyeness offers products and services including Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and Cyclosporine Eye Drops. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified.
Company details
HIS Eyeness was founded in 2017 in Bengaluru, India, within the eye care sector. A portfolio of products is developed, encompassing topical anti-infective and anti-inflammatory eye drops, dry eye therapies, preservative-free options for chronic conditions such as glaucoma, eyelid hygiene solutions, and ocular nutrients. Operations center on addressing various ocular health needs through these formulations.
- Headquarters Bengaluru, India
- Employees 90
- Stage Minicorn
- SectorsHealthcare
- Website hiseyeness.com
- Social LinkedIn X
- Legal Name His Eyeness Ophthalmics Private Limited
- Date of Incorporation 08 Aug, 2017
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹52.92 Cr
FY 2025 · +28% YoY
- Net Loss-₹4.89 Cr
FY 2025 · -9% margin
- EBITDA-₹3.51 Cr
FY 2025 · -7% margin
- Total Equity Funding$980.13K (USD)
in 5 rounds
- Latest Funding Round$33.04K (USD), Seed
Apr 2022
- Employee Count90
Associated legal entities of HIS Eyeness
HIS Eyeness is associated with 2 registered companies on The Company Check; the primary company is His Eyeness Ophthalmics Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| His Eyeness Ophthalmics Private Limited CIN U32507KA2017PTC105394 | Active | 08 Aug 2017 | Bangalore, Karnataka | ₹52.9 Cr | 90 | 3 | View details |
| His Eyeness Ophthalmics Private Limited CIN U74999KA2017PTC105394 | 08 Aug 2017 | Bangalore, Karnataka, India | View details |
Products & Services of HIS Eyeness
HIS Eyeness offers a comprehensive portfolio of products and services, including Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and Cyclosporine Eye Drops.
Eye drops to treat bacterial eye infections effectively.
Eye drops for reducing inflammation in ocular conditions.
Relieves dry eyes caused by environmental factors.
Moisturizes eyes to alleviate dryness and discomfort.
Treats inflammatory dry eye conditions with targeted therapy.
Delivers medication for chronic diseases like glaucoma safely.
Cleans eyelids to manage specific ocular health issues.
Supports overall eye health with scientifically recommended ingredients.
Funding Insights of HIS Eyeness
HIS Eyeness has successfully raised a total of $980.13K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $33.04 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $980,133
- Total Rounds 5
- Last Round Seed — $33,044
- First Round $667,661
(Nov 2017)
- Investors Count 16
All 5 funding rounds of HIS Eyeness with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $33,044 | Seed | $1.35M | Bisi Reddy | – |
| May 2021 | $49,923 | Seed | $1.28M | Nandini S Nelivigi | – |
| Apr 2020 | $106,979 | Seed | $••••• | Krimali Manthan Thacker | – |
| May 2019 | $122,526 | Seed | $••••• | Baljit Singh | |
| Nov 2017 | $667,661 | Seed | $••••• | Bisi Reddy, Mohammad Parvez |
| Date | Valuation | Stage |
|---|---|---|
| Apr 2022 | $1.35M | •••••••• |
| May 2021 | $1.28M | •••••••• |
| Apr 2020 | $••••• | •••••••• |
| May 2019 | $••••• | •••••••• |
| Nov 2017 | $••••• | •••••••• |
Full valuation and stage history of HIS Eyeness
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.35M (Apr 2022). 16 investors in total: 0 institutional and 16 angel.
Investors in HIS Eyeness
HIS Eyeness has secured backing from 16 investors, including angel investors. Prominent investors backing the company include Bisi Reddy, Nandini S Nelivigi and Krimali Manthan Thacker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
BR Bisi Reddy | Angel investor and entrepreneur, known for early-stage tech investments in India. | unknown_de72b5a4bc494be89 | ||
NS Nandini S Nelivigi | unknown_3bf4a2b0830e42b18 | |||
KM Krimali Manthan Thacker | unknown_7dce128a4bb2478e9 | |||
BS Baljit Singh | Angel investor and tech entrepreneur, focused on early-stage Indian startups. | unknown_f997953ec34847129 | ||
RC Rohan Chauhan | unknown_98c87a0027174577b | |||
BT Bhavin Trivedi | unknown_be454c0673f94d398 | |||
KS Kv Suryanarayanan | unknown_53d33c0aa8f5457e8 | |||
MP Mohammad Parvez | unknown_f1b11c10742545429 | |||
KN Kaviraju Narra | unknown_a96aae0afbf7459e9 | |||
KN Kavita Naresh Rautella | unknown_2f633a31e15c43f6b |
Investor details for HIS Eyeness
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of His Eyeness Ophthalmics Private Limited (HIS Eyeness)
His Eyeness Ophthalmics Private Limited is the primary company behind HIS Eyeness. The board of His Eyeness Ophthalmics Private Limited currently have 3 directors; the longest-serving is Suryanarayanan Krishnan, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Suryanarayanan Krishnan DIN 07885040 | Director | 08 Aug 2017 | 9 yrs 3 mo | His Eyeness Ophthalmics Private Limited |
| Senthil Kumar Rathasarathy DIN 06463295 | Director | 16 Oct 2024 | 2 yrs | His Eyeness Ophthalmics Private Limited |
| Vadakanchary Bharatha Gopal Krishnan DIN 09533369 | Director | 16 Oct 2024 | 2 yrs | His Eyeness Ophthalmics Private Limited |
Financials of HIS Eyeness
Figures of His Eyeness Ophthalmics Private Limited, the primary company behind HIS Eyeness, for FY 2025. Revenue was ₹52.92 Cr (+28% year on year). Net loss was -₹4.89 Cr (-9% margin). EBITDA was -₹3.51 Cr (-7% margin). Revenue has grown at a compounded annual rate of +46% over three years and +47% over five years.
- ₹52.92 CrRevenue · FY 2025 · +28% YoY
- -₹4.89 CrNet loss · -9% margin
- -₹3.51 CrEBITDA · -7% margin
- ₹8.3 LakhPaid-up capital
- 90Employees (provident fund records)
- +46%Revenue CAGR, 3 years
- +47%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of His Eyeness Ophthalmics Private Limited are on its company page.
Detailed financial statements for HIS Eyeness
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of HIS Eyeness
4 dated milestones of HIS Eyeness across 5 years, from founding to its latest funding, stage changes and deals.
- Founded HIS Eyeness is founded.
- Funding First funding round of $668K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Seed, of $33K.
Web traffic of HIS Eyeness
The website of HIS Eyeness (hiseyeness.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 47.7% vs previous month
Top companies in Ophthalmology
2 companies that operate in the same segment as HIS Eyeness (Ophthalmology) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about HIS Eyeness
HIS Eyeness was founded in 2017.
HIS Eyeness is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
HIS Eyeness is a funded company, having raised a total of $980.13K across 5 funding rounds to date. The company's 1st funding round was a Seed of $667.66K, raised on Nov 2017.
HIS Eyeness has 90 employees.
The primary company behind HIS Eyeness, His Eyeness Ophthalmics Private Limited, reported revenue of ₹52.92 Cr for FY 2025, up 28% year on year.
HIS Eyeness was founded in 2017 in Bengaluru, India, within the eye care sector. A portfolio of products is developed, encompassing topical anti-infective and anti-inflammatory eye drops, dry eye therapies, preservative-free options for chronic conditions such as glaucoma, eyelid hygiene solutions, and ocular nutrients. Operations center on addressing various ocular health needs through these formulations.
HIS Eyeness offers Moxifloxacin Eye Drops, Nepafenac Eye Drops, Carboxymethyl Cellulose Eye Drops, Sodium Hyaluronate Eye Drops, and 4 more products and services.
HIS Eyeness has 16 investors. Key investors include Bisi Reddy, Nandini S Nelivigi, Krimali Manthan Thacker, Baljit Singh, and Rohan Chauhan.
The valuation of HIS Eyeness is $1.35M as of Apr 2022.
HIS Eyeness operates through His Eyeness Ophthalmics Private Limited.
The legal entities of HIS Eyeness currently have 3 directors, including Senthil Kumar Rathasarathy, Suryanarayanan Krishnan, Vadakanchary Bharatha Gopal Krishnan.